Iain Kilty

Iain joined SV Health Investors as a Venture Partner in 2022 and is the CSO for SV portfolio company Sitryx Therapeutics.
Iain has over 25 years of global biopharmaceutical industry experience leading programmes from idea through to clinical development across a range of indications and therapeutic modalities.
He developed as a drug discoverer through a 22-year tenure at Pfizer, starting as an internal industrial postdoc and taking on roles of increasing responsibility working across the drug discovery paradigm from target identification to leading the early clinical cluster in Rheumatology and Dermatology.
Ultimately Iain served as Vice President Preclinical Sciences in the Inflammation and Immunology Research Unit, where he was responsible for a portfolio of both small and large molecule programmes targeted across rheumatology, dermatology and gastroenterology.
Iain left Pfizer at the end of 2018 to join Atlas Venture where he was the Chief Scientific Officer of Quench Bio, responsible for the company’s scientific strategy and execution, whilst also working as an Entrepreneur in Residence across the Atlas portfolio.
Academic Credentials Iain graduated with a BA and MA Cantab in Biochemistry from Jesus College, University of Cambridge, UK, before completing his Ph.D in the Breast Cancer Research Laboratories at the University of Liverpool, UK.